


Supplementary Figures

(A)

All
entities
(n=652)




Upregulated
FC ([drug] vs [ndrug])
n=8

Anti-diabetic drugs (n=10)

Downregulated
FC ([drug] vs [ndrug])
n=2

(C)

All entities
(n=652)




Upregulated
FC ([PPI] vs [nPPI])
n=10

proton pump inhibitor
(PPI) drugs (n=10),
thyroid hormones
drug (n=2)

Upregulated
FC ([TH] vs [nTH])
n=2

(B)

All entities
(n=652)




Upregulated
FC ([drug] vs [ndrug])
n=4

Anti-hypertensive drugs (n=5)

Downregulated
FC ([drug] vs [ndrug])
n=1

(D)

All entities
(n=652)




Upregulated
FC ([drug] vs [ndrug])
n=5

Anti-hyperlipidemic drug (n=9)


Downregulated
FC ([drug] vs [ndrug])
n=4

(E)



Supplementary Figure S1 : Determination of drug-related metabolites (drug-dependent) from the overall detected metabolites

The panels (A-E) show Venn diagrams analysis to detect the dysregulated metabolites as an effect of different drugs intake, using moderate t-test and considering fold change (FC 1.5) and p-value <0.05. (A) Metabolites dysregulated (n=10) as an effect of anti-diabetic drugs (8 upregulated and 2 downregulated), (B) Metabolites dysregulated (n=5) as an effect of anti-hypertensive drugs (4 upregulated and 1 downregulated), (C) Metabolites dysregulated as an effect of proton pump inhibitor (PPI) drugs (n=10) and thyroid hormones drugs (n=2), all were upregulated, (D) Metabolites dysregulated (n=9) as an effect of anti-hyperlipidemic (statin) drug (5 upregulated and 4 downregulated) (E) Metabolites dysregulated (n=8) as an effect of anti-osteoporotic drug (3 upregulated and 5 downregulated)



Supplementary Figure S2: Comparisons of clinical characteristics and demographic data between ON and OP groups.